Exelixis, Inc. has extended and expanded its oncology research collaboration with Bristol-Myers Squibb Company under which the two companies will continue to identify and validate molecular targets implicated in cancer. The original agreement was established for a three-year term in July 2001. Subject to the terms of their amended agreement, Exelixis and Bristol-Myers Squibb have Read more about Exelixis And Bristol-Myers Squibb Extend Oncology Collaboration[…]